Patents by Inventor Roy Curtiss

Roy Curtiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12629417
    Abstract: Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self-destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 19, 2026
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventor: Roy Curtiss
  • Patent number: 12370248
    Abstract: Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes. Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: July 29, 2025
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Roy Curtiss, Amir Ghasemi
  • Publication number: 20230279338
    Abstract: Disclosed is a live self-destructing attenuated adjuvant Salmonella strain, or a derivative thereof, capable of safe in ovo inoculation into embryonated avian eggs without reduction in hatchability. In certain examples, the live self-destructing attenuated adjuvant Salmonella strain comprises an attenuated Salmonella typhimurium (S. typhimurium) bacterium, comprising one or more mutations resulting in in vivo self-destruction selected from the group consisting of ?alr, ?dadB, ?asdA, ?PasdA::TT araC ParaBADasd, ?PdadB::TT araC ParaBADdadB, ?PasdA::TT rhaRSPrhaBADasd, ?PdadB::TT rhaRSPrhaBADdadB and/or ?PmurA::TT rhaRSPrhaBADmurA. Also disclosed are method of using the attenuated adjuvant Salmonella strains to inoculate Avian species.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 7, 2023
    Inventors: Roy CURTISS, Vinicius LIMA
  • Publication number: 20230165955
    Abstract: Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self-destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 1, 2023
    Inventor: Roy CURTISS
  • Publication number: 20230090746
    Abstract: Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers.
    Type: Application
    Filed: February 8, 2021
    Publication date: March 23, 2023
    Inventors: Roy CURTISS, Amir GHASEMI
  • Patent number: 10226521
    Abstract: Recombinant attenuated Y. pseudotuberculosis mutants have been created that show efficacy as oral vaccines against plague caused by Y. pestis and Yersinosis caused by both Y. enterocolitica and Y. pseudotuberculosis. Thus, live attenuated Y. pseudotuberculosis-based vaccines can be used to prevent Yersinosis in farm animals such as swine, cattle and sheep. The palatable baits containing live attenuated Y. pseudotuberculosis-based vaccines may be acceptable methods to control plague epidemics in wild animals. The methods disclosed can also be used to generate recombinant attenuated Y. entercolitica and Y. pestis vaccine strains.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 12, 2019
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Roy Curtiss, Wei Sun
  • Publication number: 20170049872
    Abstract: We constructed S. Gallinarum strains deleted for the global regulatory gene fur (FIG. 1) and evaluated their virulence and protective efficacy in Rhode Island Red chicks and Brown Leghorn layers. The fur deletion mutant was a virulent and, when delivered orally to chicks, elicited excellent protection against lethal S. Gallinarum challenge. We also examined the effect of a pmi mutant and a combination of fur deletions with mutations in the pmi and rfaH genes, which affect O-antigen synthesis, and ansB, whose product inhibits host T cell responses. The ?Afur ?pmi and ?fur ?ansB double mutants were attenuated, but not protective when delivered orally to chicks. However, a ?pmi ?fur strain was substantially immunogenic when administrated intramuscularly. Altogether our results show that the fur gene is essential for virulence of S. Gallinarum and the fur mutant is effective as a live recombinant vaccine against fowl typhoid.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 23, 2017
    Applicant: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Kenneth Roland, Roy Curtiss, Pawel Laniewski, Arindam Mitra
  • Patent number: 9303264
    Abstract: The present invention encompasses a photosynthetic microorganism that produces biofuels and biofuel precursors.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: April 5, 2016
    Assignee: The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, Xinyao Liu
  • Publication number: 20160089427
    Abstract: Recombinant attenuated Y. pseudotuberculosis mutants have been created that show efficacy as oral vaccines against plague caused by Y. pestis and Yersinosis caused by both Y. enterocolitica and Y. pseudotuberculosis. Thus, live attenuated Y. pseudotuberculosis-based vaccines can be used to prevent Yersinosis in farm animals such as swine, cattle and sheep. The palatable baits containing live attenuated Y. pseudotuberculosis-based vaccines may be acceptable methods to control plague epidemics in wild animals. The methods disclosed can also be used to generate recombinant attenuated Y. entercolitica and Y. pestis vaccine strains.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 31, 2016
    Applicant: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Roy Curtiss, Wei Sun
  • Publication number: 20130316458
    Abstract: The present invention encompasses a photosynthetic microorganism that produces biofuels and biofuel precursors.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 28, 2013
    Applicant: The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, Xinyao Liu
  • Publication number: 20060233829
    Abstract: A live attenuated derivative of a pathogenic bacterium intended for use as a vaccine
    Type: Application
    Filed: April 15, 2003
    Publication date: October 19, 2006
    Inventor: Roy Curtiss
  • Publication number: 20060140975
    Abstract: The present invention generally relates to regulated host-vector systems for delivery of genetic vaccine vector or desired gene products to a eukaryotic host, preparations of bacterial genetic vaccines, genetically engineered microorganisms that are useful for delivery of genetic vaccine vectors or desired gene products, and methods of use for the host-vector system.
    Type: Application
    Filed: August 29, 2003
    Publication date: June 29, 2006
    Inventors: Roy Curtiss, Wei Kong
  • Publication number: 20040208897
    Abstract: Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on differences between permissive and non-permissive environments. Viability of the microorganisms are limited to a permissive environment by specifically expressing one or more essential genes only in the permissive environment, and/or expressing one or more lethal genes only in the non-permissive environment. Temporary viability in a non-permissive environment can be achieved by temporarily expressing one or more essential genes in a non-permissive environment, and/or temporarily delaying expression of one or more lethal genes in the non-permissive environment. Environmentally Limited Viability Systems are also disclosed involving coordinate expression of a combination of essential genes and lethal genes. Microorganisms containing an Environmentally Limited Viability System are useful for release into permissive and non-permissive environments.
    Type: Application
    Filed: July 15, 2003
    Publication date: October 21, 2004
    Inventors: Roy Curtiss, Steven A. Tinge
  • Publication number: 20040120962
    Abstract: The present invention relates to immunogenic compositions comprising a live attenuated derivative of a pathogenic Enterobacteriaceae bacteria. The attenuated derivative of a pathogenic Enterobacteriaceae bacteria comprises a polynucleotide that encodes a foreign antigen. The attenuated derivative of the pathogenic Enterobacteriaceae bacteria has increased expression of Type 1 fimbriae relative to the pathogenic Enterobacteriaceae bacteria from which the attenuated derivative was derived. The present invention also relates to immunogenic compositions that elicit an enhanced Th2 immune response in an individual. The present invention further provides a method of modulating the immune response of an individual comprising administering to said individual the immunogenic compositions of the present invention.
    Type: Application
    Filed: April 15, 2003
    Publication date: June 24, 2004
    Inventors: Roy Curtiss, Ho Young Kang
  • Publication number: 20040101531
    Abstract: Disclosed are vaccines and immunogenic compositions which use live attenuated pathogenic bacteria, such as Salmonella, to deliver ectopic antigens to the mucosal immune system of vertebrates. The attenuated pathogenic bacteria are engineered to secrete the antigen into the periplasmic space of the bacteria or into the environment surrounding the bacteria. The vertebrate mounts a Th2-mediated immune response toward the secreted antigen.
    Type: Application
    Filed: April 15, 2003
    Publication date: May 27, 2004
    Inventors: Roy Curtiss, Ho Young Kang
  • Publication number: 20030031683
    Abstract: Attenuated immunogenic bacteria having an RpoS+ phenotype, in particular, Salmonella enterica serotype Typhi having an RpoS+ phenotype and methods therefor are disclosed. The Salmonella have in addition to an RpoS+ phenotype, an inactivating mutation in one or more genes which render the microbe attenuated, and a recombinant gene capable of expressing a desired protein. The Salmonella are attenuated and have high immunogenicity so that they can be used in vaccines and as delivery vehicles for genes and gene products. Also disclosed are methods for preparing the vaccine delivery vehicles.
    Type: Application
    Filed: May 3, 2002
    Publication date: February 13, 2003
    Inventors: Roy Curtiss, Cheryl A. Nickerson